Nostos Genomics enters into partnership with Genomenon: Jointly, the companies aim to accelerate the diagnosis of genetic diseases

02. June 2021

Nostos Genomics enters into partnership with Genomenon

Jointly, the companies aim to accelerate the diagnosis of genetic diseases

© Nostos Genomics

© Nostos Genomics

Nostos Genomics, a company based at the CHIC Charlottenburg Innovation Centre, announced a partnership with Genomenon, which includes integration of the Mastermind® Genomic Search Engine into the company’s cloud-based AION variant interpretation platform. This integration will allow users of the variant interpretation platform AION to preview the number of published articles related to their search and easily link out to view the evidence in Mastermind.

‍Leveraging genetic data and clinical evidence is the key to improving the diagnosis of rare diseases and making informed decisions with confidence. This integration of virtually all relevant literature into the genomic analysis process will empower clinical decision-makers to both maximize and act on profound insights contained in next generation sequencing data.

‍Mastermind connects patient genetic data with relevant evidence from scientific literature – an essential component of precision medicine for cancer and genetic disease. Using an AI-driven algorithm to index the full text of millions of genomic research articles, Mastermind has created a comprehensive database of over 7 million published variants across all genes and gene elements, updated on a weekly basis.

‍Nostos Genomics’ AION platform enhances genetic variant interpretation for clinical genetic testing by leveraging AI and functional genomics. Their white-box approach allows users to access a regularly updated knowledge repository with more than 100 annotations, including a selection of data from high-throughput functional genomics assays that directly reflect the molecular impact of thousands of selected mutations.

“This collaboration stemmed from a shared desire to not only provide clinicians with the best decision support possible, but also improve the accuracy, speed, and accessibility of genetic testing to lessen the burden of the diagnostic odyssey for patients,” said David Gorgan, CEO of Nostos Genomics.‍ “The synergy of AION with Mastermind represents an exciting development for this important work.”

“We’re excited to partner with Nostos Genomics to put the most comprehensive and up-to-date genomic research in the hands of geneticists and researchers to accelerate rare disease diagnosis,” said Mike Klein, CEO of Genomenon. “Our relationship extends Mastermind’s global reach and connecting Mastermind with AION provides significant value in cutting turnaround time and increasing diagnostic yield for genetic testing labs.”
 

About Genomenon

Genomenon is an AI-driven genomics company that organizes the world’s genomic knowledge to connect patient DNA to scientific research in the diagnosis and development of treatments for patients with rare genetic diseases and cancer.
Genomenon was named Global Company of the Year in Clinical Genomics Interpretation by Frost & Sullivan.

 

Contact:

Nostos Genomics GmbH
Bismarckstraße 10-12, 10625 Berlin
+49 30 2099 4929
Email: team@nostos-genomics.com
www.nostos-genomics.com

 

Press release Nostos Genomics June 2021